Scholarlink

Purpose <p>In breast cancer, a low skeletal muscle index (SMI) and prognostic nutritional index (PNI) negatively affect patient outcomes. However, the prognostic implications of changes in these values in patients with metastatic breast cancer (MBC) remain unclear. We evaluated the association between baseline levels and changes in SMI and PNI during eribulin treatment and patient outcomes.</p> Methods <p>We retrospectively analyzed 67 patients with MBC treated with eribulin. SMI and PNI were assessed at baseline (pre-SMI, and pre-PNI) and at disease progression; changes from baseline were calculated. Patient outcomes were compared according to baseline status and direction of change.</p> Results <p>SMI and PNI were not significantly correlated (<i>p</i> = 0.26, R = 0.02). High pre-SMI and high pre-PNI were associated with significantly improved overall survival (OS) (SMI; hazard ratio [HR] = 0.54, <i>p</i> = 0.04, PNI; HR = 0.33, <i>p</i> &lt; 0.001). Patients with SMI gain during eribulin had longer OS than those with stable SMI or loss (HR = 0.48,<i> p</i> = 0.04), whereas PNI increase was not significantly associated with OS (HR = 0.74,<i> p</i> = 0.32).</p> Conclusion <p>Baseline SMI and PNI provide complementary prognostic information in patients with MBC receiving eribulin. Furthermore, on-treatment SMI gain, but not PNI increase, was associated with improved survival. Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月15日

查看全文
  • Masatsugu Amitani,
  • Takaaki Oba,
  • Ayaka Kitazawa,
  • Ryoko Iji,
  • Nami Kiyosawa,
  • Shota Katsuyama,
  • Hiroki Morikawa,
  • Tatsunori Chino,
  • Tadafumi Shimizu,
  • Mayu Ono,
  • Toshiharu Kanai,
  • Ken-ichi Ito

摘要

Purpose

In breast cancer, a low skeletal muscle index (SMI) and prognostic nutritional index (PNI) negatively affect patient outcomes. However, the prognostic implications of changes in these values in patients with metastatic breast cancer (MBC) remain unclear. We evaluated the association between baseline levels and changes in SMI and PNI during eribulin treatment and patient outcomes.

Methods

We retrospectively analyzed 67 patients with MBC treated with eribulin. SMI and PNI were assessed at baseline (pre-SMI, and pre-PNI) and at disease progression; changes from baseline were calculated. Patient outcomes were compared according to baseline status and direction of change.

Results

SMI and PNI were not significantly correlated (p = 0.26, R = 0.02). High pre-SMI and high pre-PNI were associated with significantly improved overall survival (OS) (SMI; hazard ratio [HR] = 0.54, p = 0.04, PNI; HR = 0.33, p < 0.001). Patients with SMI gain during eribulin had longer OS than those with stable SMI or loss (HR = 0.48, p = 0.04), whereas PNI increase was not significantly associated with OS (HR = 0.74, p = 0.32).

Conclusion

Baseline SMI and PNI provide complementary prognostic information in patients with MBC receiving eribulin. Furthermore, on-treatment SMI gain, but not PNI increase, was associated with improved survival. Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy.